Daré Bioscience, Inc.
DARE
$2.93
-$0.055-1.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -99.65% | 88.13% | -- | -71.83% | -71.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.65% | 88.13% | -- | -71.83% | -71.92% |
| Cost of Revenue | -33.89% | -28.19% | -28.19% | -28.19% | -28.21% |
| Gross Profit | 24.08% | 32.18% | 37.61% | 6.52% | 6.51% |
| SG&A Expenses | -23.12% | -16.98% | -11.27% | -6.39% | 5.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.07% | -42.05% | -27.37% | -24.59% | -18.94% |
| Operating Income | 23.71% | 45.15% | 34.34% | 9.53% | 2.06% |
| Income Before Tax | 86.56% | 91.22% | 81.89% | 5.61% | 2.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.56% | 91.22% | 81.89% | 5.61% | 2.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.56% | 91.22% | 81.89% | 5.61% | 2.54% |
| EBIT | 23.71% | 45.15% | 34.34% | 9.53% | 2.06% |
| EBITDA | 23.75% | 45.21% | 34.40% | 9.57% | 2.10% |
| EPS Basic | 87.68% | 91.08% | 81.37% | 13.53% | 7.73% |
| Normalized Basic EPS | 85.77% | 91.55% | 81.85% | 14.15% | 8.35% |
| EPS Diluted | 87.27% | 90.76% | 81.05% | 13.38% | 7.59% |
| Normalized Diluted EPS | 85.48% | 91.35% | 81.65% | 14.16% | 8.36% |
| Average Basic Shares Outstanding | 14.14% | 13.58% | 12.32% | 8.58% | 4.61% |
| Average Diluted Shares Outstanding | 14.36% | 13.81% | 12.55% | 8.35% | 4.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |